Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Portfolio diversification progressing CHFM 30,713 Diversification of Roche business +5% at CER +64 -987 +627 + 1,576 +392 HY 2017 CHF 26.3bn -90 32,295 HY 2021 Diagnostics Diagnostics Pharma Ronapreve AHR base COVID-19 underlying sales erosion1 business sales business Fx HY 2022 HY 2022 values in reported CHFm, variances in CERm; 1AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion (2.5bn for FY 2022) AHR Diagnostics Other pharma Ophthalmology Infectious diseases Immunology HY 2022 CHF 32.3bn AHR Oncology AHR Neuroscience Hemophilia A Roche 9

View entire presentation